


Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I):



and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.

2. (Original) The glycine conjugate of the compound of formula (I):



(I).

5. (Previously Presented) The compound of claim 13, wherein said compound is tritiated.

12. (Previously Presented) A pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

14. (Previously Presented) A method for the treatment of an FXR mediated disease or condition in a mammal comprising administering to a mammal suffering from an FXR mediated disease or condition a therapeutically effective amount of a compound according to claim 1, wherein said FXR mediated disease or condition is selected from the group consisting of hypercholesteremia, hyperlipidemia, low HDL-cholesterol, and high triglycerides.

15. (Previously Presented) A method for the treatment of cardiovascular disease in a mammal comprising administering to a mammal suffering from a cardiovascular disease a therapeutically effective amount of a compound according to claim 1, wherein said cardiovascular disease is selected from the group consisting of arteriosclerosis and hypercholesteremia.

16. (Previously Presented) The method according to claim 15, wherein said cardiovascular disease is arteriosclerosis.

17. (Previously Presented) A method for increasing HDL cholesterol in a mammal, said method comprising administering to a mammal whose HDL cholesterol is to be increased a therapeutically effective amount of a compound according to claim 1.

18. (Previously Presented) A method for lowering triglycerides in a mammal, said method comprising administering to a mammal whose triglycerides are to be lowered a therapeutically effective amount of a compound according to claim 1.